Cholrem Pty Ltd is a specialty bio-pharmaceutical company established in 2018 to explore the possibility of Cyclodextrin becoming a treatment for cardiovascular disease.

Leveraging advanced proprietary technologies, Cholrem set out to develop first-in-class drugs to treat and remove harmful cholesterol from the vascular system.

Scientific studies and research into cyclodextrin are showing that enhanced cholesterol transport within the body has major benefits in a huge range of health issues, including Atherosclerosis, Alzheimer disease, Kidney disease, Macula degeneration etc.

Cholrem Pty Ltd conducted world first trials using HP-B-CD with patients suffering advanced cardiovascular disease. The results showed substantial plaque reduction within 4 weeks of treatment.

Advancements in our development of Cyclodextrin resulted in our creation of CAVADEX®, a proprietary Cyclodextrin that is shown to have enhanced cholesterol transport and removal from the vascular system without any adverse side effects.

Visit our American company website